Cartesian Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RNAC research report →
About the company
Cartesian Therapeutics, Inc. , a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
- CEO
- Carsten Brunn
- IPO
- 2016
- Employees
- 75
- HQ
- Frederick, MD, US
Price Chart
- Market Cap
- $311.15M
- P/E
- -1.83
- P/S
- 175.30
- P/B
- -1.92
- EV/EBITDA
- -1.29
- Div Yield
- 0.00%
- Gross Margin
- -620.96%
- Op Margin
- -5144.51%
- Net Margin
- -8550.65%
- ROE
- 194.13%
- ROIC
- -31.12%
- Revenue
- $2.80M · -92.81%
- Net Income
- $-130,302,000 · -68.30%
- EPS
- $-5.02 · -67.89%
- Op Income
- $-86,705,000
- FCF YoY
- -142.30%
- 52W High
- $15.57
- 52W Low
- $5.60
- 50D MA
- $7.82
- 200D MA
- $7.70
- Beta
- 0.46
- Avg Volume
- 290.28K
Get TickerSpark's AI analysis on RNAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Hoge Elizabeth | other | 758,001 |
| Apr 2, 26 | Hoge Elizabeth | other | 22,740.03 |
| Apr 2, 26 | Kalayoglu Murat | other | 758,001 |
| Apr 2, 26 | Kalayoglu Murat | other | 22,740.03 |
| Mar 13, 26 | Singer Michael | other | 6,555 |
| Jan 6, 26 | Brunn Carsten | sell | 23,766 |
| Jan 6, 26 | Miljkovic Milos | sell | 3,573 |
| Jan 6, 26 | Davis Blaine | sell | 10,591 |
| Jan 2, 26 | DeSilva Nishan M | other | 2,600 |
| Jan 2, 26 | DeSilva Nishan M | other | 7,800 |
Our RNAC coverage
Recent articles, reports, and earnings notes.
No research on RNAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RNAC report →Similar companies
Peers in the same neighborhood.